Jackson Creek Investment Advisors LLC Makes New $1.03 Million Investment in Soleno Therapeutics, Inc. $SLNO

Jackson Creek Investment Advisors LLC purchased a new stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 15,200 shares of the company’s stock, valued at approximately $1,028,000.

Other institutional investors also recently modified their holdings of the company. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. acquired a new stake in Soleno Therapeutics in the second quarter valued at about $42,089,000. Sofinnova Investments Inc. boosted its stake in shares of Soleno Therapeutics by 1,026.2% in the 2nd quarter. Sofinnova Investments Inc. now owns 415,219 shares of the company’s stock valued at $34,787,000 after purchasing an additional 460,048 shares in the last quarter. Balyasny Asset Management L.P. grew its holdings in shares of Soleno Therapeutics by 1,206.9% during the 2nd quarter. Balyasny Asset Management L.P. now owns 361,605 shares of the company’s stock valued at $30,295,000 after purchasing an additional 394,273 shares during the last quarter. Geode Capital Management LLC increased its position in Soleno Therapeutics by 46.6% during the 2nd quarter. Geode Capital Management LLC now owns 902,396 shares of the company’s stock worth $75,611,000 after purchasing an additional 286,660 shares in the last quarter. Finally, State Street Corp lifted its stake in Soleno Therapeutics by 20.2% in the 2nd quarter. State Street Corp now owns 1,404,983 shares of the company’s stock valued at $117,709,000 after purchasing an additional 235,784 shares during the last quarter. Institutional investors and hedge funds own 97.42% of the company’s stock.

Soleno Therapeutics Trading Up 9.8%

NASDAQ SLNO opened at $42.32 on Tuesday. The firm has a market capitalization of $2.27 billion, a PE ratio of -23.00 and a beta of -3.16. The business’s 50-day moving average price is $46.51 and its two-hundred day moving average price is $59.13. The company has a current ratio of 16.08, a quick ratio of 15.88 and a debt-to-equity ratio of 0.10. Soleno Therapeutics, Inc. has a 12 month low of $37.95 and a 12 month high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last announced its earnings results on Tuesday, November 4th. The company reported $0.47 EPS for the quarter, beating the consensus estimate of $0.08 by $0.39. The company had revenue of $66.02 million during the quarter, compared to the consensus estimate of $47.46 million. On average, analysts expect that Soleno Therapeutics, Inc. will post -3.72 EPS for the current year.

Wall Street Analyst Weigh In

SLNO has been the topic of a number of research reports. Wolfe Research set a $60.00 target price on shares of Soleno Therapeutics in a research note on Monday, January 12th. Wells Fargo & Company restated an “overweight” rating and set a $114.00 price objective (up previously from $106.00) on shares of Soleno Therapeutics in a research report on Tuesday, January 20th. HC Wainwright reiterated a “buy” rating and issued a $120.00 target price (up from $110.00) on shares of Soleno Therapeutics in a research report on Tuesday, January 20th. Robert W. Baird set a $107.00 price target on Soleno Therapeutics in a report on Tuesday, January 13th. Finally, Wall Street Zen raised Soleno Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $110.62.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.